Trial Profile
Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Penile cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms CaboPen
- 17 Oct 2019 Status changed from not yet recruiting to recruiting.
- 14 Oct 2017 New trial record
- 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.